IGF1 and Alzheimer disease: Conversely, in the work of Bot et al., in 2016, it was found that levels of peripheral IGF-1 were significantly increased in depressive patients under AD treatment, but significantly decreased in patients that were non-responders, and who were not following AD treatment [41].